NEJM Publishes Full Results of Retatrutide Trials for Obstructive Sleep Apnea
Start here
The New England Journal of Medicine has published the full texts of TRIUMPH-1-OSA and TRIUMPH-2-OSA, two trials evaluating once-weekly retatrutide, a triple-agonist incretin therapy, in patients with obstructive sleep apnea. The papers come from the investigator teams of both trials. The publications mark the peer-reviewed disclosure of the complete datasets for retatrutide in this indication, a potential first-in-class pharmacological approach beyond weight loss alone for sleep apnea. Detailed endpoint and safety results from the articles have not yet been extracted and will be added to this page as the data are reviewed. Open questions include the magnitude of effect on apnea-hypopnea index, safety and tolerability findings, and how the results may position retatrutide against other incretin therapies under study for sleep-disordered breathing.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- New England Journal of MedicinePickRetatrutide Once Weekly for Treatment of Obstructive Sleep Apnea
NEJM has published the full papers of TRIUMPH-OSA, two phase three trials of once-weekly retatrutide for obstructive sleep apnea. The authors are the investigator teams of the trials; detailed endpoint and safety data will be added once the full text becomes available.
Coverage and heat for this story
Reports so far 1·Heat now 8·Peak heat 10 (Oct 21 14:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.